SAN DIEGO, July 30, 2026 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
